A STUDY TO ASSESS THE LONG-TERM SAFETY AND | Clinical Research Studies Listing

A STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF INTRAVENOUS ATB200 CO-ADMINISTERED WITH ORAL AT2221 IN ADULT SUBJECTS WITH LATE-ONSET POMPE DISEASE

Enrolling By Invitation

18 years - 99 years

All

Phase 3

3 participants needed

1 Location

Brief description of study

A STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF INTRAVENOUS ATB200 CO-ADMINISTERED WITH ORAL AT2221 IN ADULT SUBJECTS WITH LATE-ONSET POMPE DISEASE

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: POMPE DISEASE,POMPE DISEASE
Age: 18 years - 99 years
Gender: All

completion of study ATB200-03 Male Female over age 18

Updated on 04 Aug 2024. Study ID: 843492

If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245